Adam Koppel
Adam Koppel's purchase track record
Adam Koppel has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/20/2026 | KLRA | $25.00M | -27.2% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
SLDB Featured in After-Market Movers List. Solid Biosciences was included in a Benzinga list of healthcare stocks moving in Friday's after-market session. The stock is currently trading near its 52-week low, with an RSI of 20.5 indicating oversold conditions. Analysts maintain an average price target of $18.62, which is significantly higher than the current trading range.
Transaction History
| KLRA | ▼ Sell | Other | 16,875,000 | — | 4/20/2026 | View on chart |
| KLRA | ▼ Sell | Other | 4,145,768 | — | 4/20/2026 | View on chart |
| KLRA | ▲ Buy | Open Market | 1,562,500 | $25.0M | 4/20/2026 | View on chart |
| SLDB | ▲ Buy | Grant | 904,160 | $5.0M | 1/11/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation
Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.